Welcome to Asklepion Pharmaceuticals.

Asklepion is focused on the discovery, development, and commercialization of pharmaceutical products to help patients who have little to no therapeutic options, due to the rarity of their conditions. Read more about the company here.

Latest News

L-citrulline pivotal Phase III trial initiated in July 2016

Liquid formulation of ursodeoxycholic acid strategically divested to Retrophin, Inc. in June 2016.

Cholbam® (cholic acid) oral capsules approved by the F.D.A. in March 2015

Asklepion aims to provide treatment options for children with rare diseases.
Pipeline Executives